Perimenopause and ADHD: When Everything Falls Apart

Something shifted, and you can not quite explain what. You used to be able to hold it all together: the job, the house, the family, the mental load. Maybe it was never easy, but you managed. And now, in your late 30s or 40s, it feels like your brain has stopped cooperating.

You are losing your keys. You can not finish sentences. Your to-do list feels impossible. You are emotionally reactive in ways that surprise you. And the brain fog is relentless.

If this sounds familiar, you are not alone, and you are not losing your mind. For many women, the perimenopause transition marks a turning point where ADHD symptoms that were previously manageable become overwhelming, or where ADHD-like symptoms appear for what feels like the first time. Understanding why this happens is the first step toward getting the right support.

Why Perimenopause Changes Everything

Perimenopause is the transitional phase leading up to menopause, the point at which menstrual periods stop permanently. For most women, perimenopause begins in the early to mid-40s, though it can start as early as the mid-30s. The transition can last anywhere from 4 to 15 years.

What makes perimenopause so disruptive is not simply that hormone levels decline. It is that they become erratic. Estrogen does not drop in a smooth, predictable curve. Instead, it fluctuates wildly, sometimes spiking to levels higher than normal reproductive levels, then plummeting dramatically. Progesterone also declines, typically more steadily, as ovulation becomes irregular.

This hormonal volatility has direct consequences for brain function. Estrogen supports dopamine synthesis, receptor sensitivity, and reuptake regulation. When estrogen levels swing unpredictably, so does the dopamine system. Serotonin, which is also influenced by estrogen, fluctuates as well, contributing to mood changes, sleep disruption, and anxiety.

For women with ADHD, this hormonal instability can feel catastrophic. The dopamine system that was already functioning suboptimally now loses one of its key supporting hormones. Coping strategies that worked for decades may suddenly fail, not because you have changed, but because the neurochemical landscape beneath those strategies has shifted.

What the Research Shows

A landmark 2025 population-based cohort study from Iceland examined perimenopausal symptoms in over 5,300 women aged 35 to 55. The findings were striking: women with ADHD experienced more severe perimenopausal symptoms across all domains including psychological, somatic, and urogenital symptoms. Perhaps most significantly, the severity gap between women with and without ADHD peaked between ages 35 and 39, suggesting that perimenopausal symptoms may begin up to a decade earlier in women with ADHD.

A 2025 study in the Journal of Attention Disorders found that ADHD-like symptoms, measured on the Brown Attention Deficit Disorder Scale, increased as women moved from pre-menopause to perimenopause, with a partial recovery in natural postmenopause. This pattern is consistent with what we would expect if fluctuating and declining estrogen is driving symptom worsening: the most volatile phase (perimenopause) produces the most symptoms.

In a large survey of nearly 5,000 women with ADHD conducted by ADDitude Magazine, 63% of respondents aged 45 and older identified perimenopause and menopause as the life stage when ADHD had the greatest impact on their lives. Over 93% reported noticing a difference in symptom severity during this transition.

However, it is essential to acknowledge that the research base remains limited. As one review noted, there are still no studies that specifically examine menopause in women with confirmed ADHD diagnoses using prospective, controlled designs. Much of what we know comes from surveys, cross-sectional studies, and clinical observation. The science is advancing rapidly, but we are still in the early stages of understanding this intersection.

Is It ADHD, Perimenopause, or Both?

One of the biggest challenges during this transition is figuring out what is actually going on. The symptom overlap between ADHD and perimenopause is substantial. Both can cause difficulty concentrating, forgetfulness, brain fog, emotional reactivity, sleep disruption, and fatigue.

There are some distinguishing features that can help:

Timing matters. ADHD is a neurodevelopmental condition that typically shows evidence going back to childhood or early adulthood, even if it was not recognized at the time. Perimenopause symptoms have a clear onset in midlife. If cognitive difficulties are truly new, with no prior history of attention or organizational struggles, perimenopause may be the primary driver.

Consistency matters. ADHD symptoms tend to be present across many settings and situations, though they may wax and wane. Perimenopause-related cognitive changes may be more fluctuating and more clearly tied to other symptoms like hot flashes, night sweats, or mood changes.

History matters. Many women who present with “new” cognitive difficulties in their 40s actually have a lifelong pattern of subtle ADHD that was compensated for and masked. Careful history-taking that explores childhood patterns, academic history, and earlier life challenges can reveal an ADHD pattern that was always there.

In practice, many women are dealing with both: longstanding ADHD that is being worsened by perimenopause. The two are not mutually exclusive, and in fact, they frequently coexist.

The Role of Progesterone and GABA

While estrogen and dopamine get the most attention in the ADHD conversation, progesterone plays an important role as well. Progesterone is metabolized in the brain into allopregnanolone, a neurosteroid that acts as a powerful positive modulator of GABA-A receptors. GABA is the brain’s primary inhibitory neurotransmitter, essential for calm, sleep, and emotional regulation.

During perimenopause, as ovulation becomes irregular and eventually stops, progesterone production declines significantly. This means less allopregnanolone, less GABA-A receptor modulation, and potentially less of the calming, sleep-promoting neurosteroid activity that many women rely on without knowing it.

For women with ADHD, this can compound the problem. ADHD already involves difficulty with emotional regulation and arousal management. Losing the calming influence of progesterone-derived neurosteroids on top of the dopamine disruption from estrogen decline creates a situation where both the “gas” (dopamine for focus and motivation) and the “brakes” (GABA for calm and regulation) are compromised simultaneously.

Treatment Approaches: What Can Help

ADHD Medication

Standard ADHD medications, including stimulants and non-stimulants, remain the first-line treatment for ADHD symptoms during perimenopause. Some women who were stable on medication may need dosing adjustments during this transition. Others who have never been treated for ADHD may benefit from medication for the first time.

A notable finding from recent research is that psychostimulants may improve midlife-onset executive function difficulties in perimenopausal and early postmenopausal women, even in some who do not have a formal ADHD diagnosis. This supports the idea that the dopaminergic disruption of perimenopause creates real, treatable cognitive impairment.

Hormone Replacement Therapy Considerations

Hormone replacement therapy (HRT), particularly estrogen therapy, has shown benefits for cognitive function and mood during the menopausal transition in some women. Because estrogen supports dopamine function, there is a logical rationale for exploring whether HRT might also help with ADHD symptoms.

However, the evidence specifically linking HRT to ADHD symptom improvement is limited. In the ADDitude survey, about a third of women with ADHD had tried HRT, and roughly a quarter of those found it helpful. This is suggestive but far from definitive.

What is clear is that HRT decisions are complex, involving considerations of cardiovascular risk, breast cancer history, personal and family health factors, and individual symptom profiles. These decisions belong in the domain of gynecology and endocrinology, ideally in collaboration with psychiatry when ADHD is part of the picture.

Progesterone for Sleep and Calming

In an integrative psychiatric practice, progesterone may be considered for its neurosteroid effects, particularly its sleep-promoting and anxiety-reducing properties through GABA-A receptor modulation. This is distinct from hormone replacement therapy and is used specifically for its neuro-calming effects in the context of comprehensive psychiatric care. (For a deeper exploration of this topic, see Blog 4.4: Progesterone, GABA, and the Calm Brain.)

Comprehensive Lifestyle Support

The fundamentals become even more important during perimenopause: consistent sleep hygiene, regular exercise (which supports both dopamine function and hormonal health), blood sugar stability, stress management, and reducing cognitive load where possible. These are not substitutes for medical treatment, but they create a foundation that makes everything else work better.

Collaborative Care

Perimenopause with ADHD is a situation that benefits from collaborative care between psychiatry and gynecology (or endocrinology). The hormonal and neurocognitive dimensions are interconnected, and a treatment plan that addresses both is more likely to succeed than one that focuses on either in isolation.

When to Seek Evaluation

Consider seeking a comprehensive evaluation if any of the following resonate with you:

• Your cognitive function has changed significantly in your late 30s or 40s, and you are struggling with focus, organization, or memory in ways that feel new or much worse.
• You have been treated for anxiety or depression, but something still feels unresolved.
• You recognize a pattern of attention or executive function difficulties that actually stretches back further than you initially thought.
• Your current ADHD treatment has stopped working as well as it used to, coinciding with perimenopausal changes.
• You are experiencing sleep disruption, emotional reactivity, and cognitive fog that are significantly affecting your daily functioning and relationships.

A thorough evaluation should consider ADHD, hormonal factors, thyroid function, mood disorders, sleep quality, and the full context of your health history. The goal is not to find a single label, but to understand all the factors contributing to how you feel and build a treatment plan that addresses the whole picture.

Key Takeaways

• Perimenopause can unmask previously compensated ADHD or dramatically worsen existing symptoms due to erratic estrogen fluctuations disrupting dopamine function.
• Women with ADHD may experience more severe perimenopausal symptoms that begin up to 10 years earlier than women without ADHD.
• The symptom overlap between ADHD and perimenopause is substantial, making accurate diagnosis challenging but essential.
• Progesterone decline during perimenopause compounds the problem by reducing GABA-A receptor modulation, affecting sleep and emotional regulation.
• Treatment often requires a combination of ADHD medication, hormonal considerations, lifestyle support, and collaborative care between psychiatry and gynecology.
• The research is advancing rapidly, but controlled studies specifically examining ADHD during menopause remain limited.

Frequently Asked Questions

Can perimenopause cause ADHD?

Perimenopause does not cause ADHD, which is a neurodevelopmental condition with roots in brain development and genetics. However, the hormonal changes of perimenopause can unmask ADHD that was previously compensated for, or significantly worsen existing symptoms. Many women receive their first ADHD diagnosis during this transition because their coping mechanisms can no longer keep up with the additional neurochemical disruption.

At what age does perimenopause typically start?

For most women, perimenopause begins in the early to mid-40s, though it can start as early as the mid-30s. Research suggests that women with ADHD may begin experiencing perimenopausal symptoms up to 10 years earlier than women without ADHD, with the severity gap peaking between ages 35 and 39.

Will HRT help my ADHD symptoms?

The evidence for HRT specifically improving ADHD symptoms is limited but suggestive. Some women with ADHD report cognitive improvements with estrogen therapy, which is consistent with the estrogen-dopamine connection. However, HRT decisions are complex and should be made in consultation with your gynecologist or endocrinologist, ideally in collaboration with your psychiatrist.

Should I adjust my ADHD medication during perimenopause?

Many women need medication adjustments during perimenopause. If you notice your medication becoming less effective, this is worth discussing with your prescriber. Dosing adjustments, timing changes, or the addition of supportive treatments may be helpful.

How do I tell if my brain fog is from perimenopause or ADHD?

A careful clinical history is the most important tool. ADHD symptoms typically have evidence going back to earlier in life, even if they were mild or well compensated. Perimenopause-related cognitive changes have a clear midlife onset and may fluctuate with other perimenopausal symptoms. Many women in this age group are experiencing both, and a comprehensive evaluation can help sort this out.

References

1. Borg Skoglund L, et al. Perimenopausal symptoms in women with and without ADHD: a population-based cohort study. BMC Medicine. 2025. SAGA cohort, n=5,392.
2. Chapman L, Gupta K, Hunter MS, Dommett EJ. Examining the link between ADHD symptoms and menopausal experiences. Journal of Attention Disorders. 2025. doi:10.1177/10870547251355006
3. Page SA, et al. ADHD-like symptoms across the menopausal transition using the Brown Attention Deficit Disorder Scale. Study, n=1,971.
4. Wasserstein J, Stefanatos GA, Solanto M. ADDitude Magazine survey of women with ADHD and menopause, n=4,000+. 2024-2025.
5. Kooij S, Jong M de, Agnew-Blais J, et al. Research advances and future directions in female ADHD. Frontiers in Global Women’s Health. 2025;6. doi:10.3389/fgwh.2025.1613628
6. Osianlis E, Thomas EHX, Jenkins LM, Gurvich C. ADHD and sex hormones in females: a systematic review. Journal of Attention Disorders. 2025;29(9):706-723. doi:10.1177/10870547251332319
7. Dorani F, Bijlenga D, Beekman ATF, van Someren EJW, Kooij JJS. Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research. 2021. doi:10.1016/j.jpsychires.2020.12.005
8. Epperson CN, Shanmugan S, Kim DR, et al. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology. 2015;232(16):3091-3100.
9. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. Journal of Steroid Biochemistry and Molecular Biology. 2014;142:90-98.
10. Eng AG, Nirjar U, Elkins AR, et al. Attention-deficit/hyperactivity disorder and the menstrual cycle: theory and evidence. Hormones and Behavior. 2024;158:105466.
11. Yang JL, Hodara E, Sriprasert I, Shoupe D, Stanczyk FZ. Estrogen deficiency in the menopause and the role of hormone therapy. 2024.

Medical Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making changes to your treatment plan. Decisions about hormone therapy should be made in consultation with your gynecologist or endocrinologist.